Frontage

Frontage Laboratories presents itself as a global pharmaceutical development organization and a collaborative, science-driven partner for drug discovery and development. Its services cover much of the pharmaceutical research and development pathway, from discovery research and preclinical work through clinical support, laboratory testing, and product development and manufacturing. The company describes its work as helping clients address complex drug discovery and development challenges. Its drug-discovery offering includes chemistry, biology, ADME/tox screening, and pharmacology. Development services include drug metabolism and pharmacokinetics (DMPK), preclinical safety and toxicology, and clinical trial services. Laboratory testing capabilities include bioanalysis for small and large molecules, genomics, central laboratory services, biomarkers, and precision medicine. The company also identifies central-lab histology and pathology, clinical sample processing, biospecimen and data services, and clinical-trial logistics among its offerings. Frontage also offers chemistry, manufacturing, and controls (CMC) capabilities as a full-spectrum contract development and manufacturing organization (CDMO). Its website describes product-development and manufacturing services that include drug-substance development and manufacturing, formulation development, clinical-trial material manufacturing, commercial manufacturing, and analytical services. These offerings position the company as a service provider to pharmaceutical and biotechnology clients rather than as a consumer-facing medicine brand. The company’s published history describes expansion through acquisitions and facility investment in North America, Europe, and China. The cited timeline records acquisitions involving toxicology and testing, genomics, Canadian preclinical services, and Italian bioanalytical and DMPK businesses, as well as a large DMPK and safety-and-toxicology facility in Suzhou. Frontage’s site also reports that it completed the acquisition of Teddy Lab in 2026. The supplied material does not establish its founding year, founder, headquarters, current parent or ownership structure, or named executives.

Frontage Laboratories is presented on its official website as a global pharmaceutical development organization. Its service model spans drug discovery, preclinical and clinical development support, laboratory testing, and CMC product development and manufacturing. The supplied official materials do not state the company’s founding date or founder, so these details cannot be established here. The company’s published timeline documents a sequence of capability expansions and acquisitions. In 2022, Frontage reported acquiring Experimur’s toxicology and testing services in Chicago and opening a 200,000-square-foot facility for DMPK and safety and toxicology in Suzhou, China. The same timeline records its acquisition of Ocean Ridge Biosciences in Deerfield, Florida, in 2021, describing that business as focused on genomics and RNA- and protein-based biomarker discovery. In 2023, Frontage completed the acquisition of Nucro-Technics Inc. and its affiliate, Nucro-Technics Holdings, Inc., in Toronto, Canada. The timeline also notes that Frontage received a 2023 CRO Leadership Award, with recognition across capabilities, compatibility, expertise, quality, and reliability. It reports a further set of CRO Leadership Awards in 2022 across those five categories. In 2024, Frontage acquired the bioanalytical and DMPK businesses of Accelera S.r.l. in Milan, Italy. In 2025, it unveiled a 46,300-square-foot GMP CRDMO facility at 240 Sierra Drive, intended to expand formulation development, manufacturing, and analytical testing capabilities. The timeline then records a 2026 acquisition of Teddy Lab, which the company says strengthened its global central laboratory capabilities. Across the materials, Frontage describes a broadening service platform: discovery chemistry and biology; ADME and toxicology screening; DMPK and safety assessment; clinical and central laboratory services; bioanalysis, genomics, and biomarker capabilities; and CMC development and manufacturing. The supplied evidence supports this account of service expansion but does not establish the company’s headquarters, current corporate ownership, listing status, or leadership.

• 2026

  Completed acquisition of Teddy Lab

• 2025

  Unveiled a GMP CRDMO facility

• 2024

  Acquired Accelera bioanalytical and DMPK businesses

• 2023

  Acquired Nucro-Technics

• 2022

  Expanded toxicology services and opened a Suzhou facility

• 2022

  Received CRO Leadership Awards

• 2021

  Acquired Ocean Ridge Biosciences

A global, science-driven pharmaceutical research and development services partner offering capabilities across discovery, development, laboratory testing, and CDMO work.

• Drug discovery services

  Services include chemistry, biology, ADME/tox screening, and pharmacology.

• Drug development services

  Services include DMPK, preclinical safety and toxicology, and clinical trial services.

• Laboratory testing services

  Capabilities include bioanalytical testing, genomics, central laboratory services, biomarkers, and precision medicine.

• CMC product development and manufacturing

  The website lists drug-substance development and manufacturing, formulation development, clinical-trial material manufacturing, commercial manufacturing, and analytical services.

• 2020.07.02

  Reported2020.07.03

  Frontage Labs announces acquisition of ACME Bioscience[4]方达控股旗下Frontage Labs宣布收购ACME Biosciencefinance.sina.com.cn

  Frontage Labs, a wholly owned subsidiary of Frontage Holdings, signed an equity transfer agreement to acquire all shares in ACME Bioscience held by Jason Zhang and other independent third parties.

• 2019.11.04

  Reported2019.11.04

  Frontage Labs announces agreement to acquire RMI Laboratories[5]方达控股宣布收购RMI Laboratoriesfinance.sina.com.cn

  Frontage Laboratories, a wholly owned subsidiary of Frontage Holdings, announced an equity purchase agreement to acquire all of RMI Laboratories’ equity from Phillip Tiller and Xiao (Sean) Yu.

Read more

1. 1Frontage Laboratories - A global pharmaceutical development organizationfrontagelab.com
2. 2History of Frontage • Frontage Laboratoriesfrontagelab.com
3. 3Histology & Pathology • Frontage Laboratoriesfrontagelab.com
4. 4方达控股旗下Frontage Labs宣布收购ACME Biosciencefinance.sina.com.cn
5. 5方达控股宣布收购RMI Laboratoriesfinance.sina.com.cn